Compare · CELZ vs NU
CELZ vs NU
Side-by-side comparison of Creative Medical Technology Holdings Inc. (CELZ) and Nu Holdings Ltd. (NU): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CELZ and NU operate in Finance: Consumer Services (Finance), so they compete in similar markets.
- NU is the larger of the two at $71.52B, about 11519.1x CELZ ($6.2M).
- NU has hit the wire 6 times in the past 4 weeks while CELZ has been quiet.
- NU has more recent analyst coverage (25 ratings vs 1 for CELZ).
Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem for the treatment of erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine for the treatment of chronic lower back pain; Amniostem for the treatment of strokes, radiation, toxicity, and glioma; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. was incorporated in 1998 and is based in Phoenix, Arizona.
Nu Holdings Ltd.
Nu Holdings Ltd. operates in the technology industry. The company was incorporated in 2016 and is based in Grand Cayman, Cayman Islands.
Latest CELZ
- President & CEO Warbington Timothy was granted 1,000,000 shares (SEC Form 4)
- Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing
- Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning
- SEC Form 10-Q filed by Creative Medical Technology Holdings Inc.
- Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
- SEC Form 424B3 filed by Creative Medical Technology Holdings Inc.
- SEC Form EFFECT filed by Creative Medical Technology Holdings Inc.
- SEC Form S-3 filed by Creative Medical Technology Holdings Inc.
Latest NU
- SEC Form 4 filed by Nu Holdings Ltd.
- SEC Form 4 filed by Nu Holdings Ltd.
- Nu Holdings Ltd. Statement Regarding Media Reports
- SEC Form 6-K filed by Nu Holdings Ltd.
- Chief Legal Officer Wilson Sarah K. was granted 1,430,908 units of Class A ordinary shares (SEC Form 4)
- SEC Form 3 filed by new insider Wilson Sarah K.
- Nu Holdings downgraded by Itau BBA with a new price target
- Nu Takes Next Step in International Expansion With Launch in the United States and introduction of Nu Global
- SEC Form 6-K filed by Nu Holdings Ltd.
- Nu Holdings Announces Investor Day for December 8, 2026